secwatch / observer
8-K filed January 8, 2024, 6:59 PM ET ticker JAZZ CIK 0001232524
earnings confidence medium sentiment positive materiality 0.50

Jazz Pharma reaffirms 2023 revenue guidance; sees 2024 double-digit growth for key drugs

Jazz Pharmaceuticals plc

2023-FY EPS reported $6.10 revenue$3,834,204,000
item 2.02item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jazz Pharmaceuticals plc updated its the year ended December 31, 2024 guidance (initiated).

Period
the year ended December 31, 2024
Guidance
initiated
Result
guidance update
Exact text from the filing
the Company's expectations that its key growth drivers, Xywav, Epidiolex, and Rylaze, are expected to have combined double-digit percentage revenue growth in 2024, and (iii) the Company's expectations with respect to the growth of high-sodium oxybate authorized generic royalty revenue for the year ended December 31, 2024
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Jazz Pharmaceuticals plc updated its the year ended December 31, 2023 guidance (reaffirmed).

Period
the year ended December 31, 2023
Guidance
reaffirmed
Result
guidance update
Exact text from the filing
the Company's expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance range for the year ended December 31, 2023
View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Jazz Pharmaceuticals plc filing history →

Source: SEC EDGAR
accession 0001193125-24-003910
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.